Related coverage linked through entity extraction aliases.
Jul 17, 2026
The FDA approved six cancer therapies in Q2 2026, including first-line sacituzumab govitecan for triple-negative breast cancer and capivasertib for PTEN-deficient prostate cancer. A separate study shows 69% of accelerated-approval cancer drugs need safety updates within 4 years.
Apr 13, 2026
Bristol Myers Squibb started a Phase 1 trial of BMS-986506 in clear cell renal cell carcinoma, triggering a $10 million milestone payment to Evotec SE. The candidate is the first molecular glue from the companies’ protein-degradation partnership to enter human testing.
Mar 12, 2026
Merck announced multiple data presentations at the 2026 ASCO GU Cancers Symposium, including results from trials evaluating pembrolizumab combinations in muscle-invasive bladder cancer and renal cell carcinoma.
Mar 02, 2026
Phase III trial demonstrates belzutifan plus lenvatinib significantly improved progression-free survival versus cabozantinib in previously treated renal cell carcinoma patients, while neoadjuvant studies show promise for locally advanced disease.
